This report studies the global ICAD (Intracranial Atherosclerotic Disease) Pathology market status and forecast, categorizes the global ICAD (Intracranial Atherosclerotic Disease) Pathology market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa).
Intracranial atherosclerotic disease is the progressive narrowing of the cerebral arteries within the skull (intracranial). The arteries that supply oxygen-enriched blood to the brain are the carotid arteries and the vertebral arteries. The circle of Willis is the area at the base of the brain that joins these arteries.
The classification of ICAD (Intracranial Atherosclerotic Disease) Pathology includes Stent and PTA Balloon, and the proportion of Stent in 2017 is about 80.15%.
ICAD (Intracranial Atherosclerotic Disease) Pathology is widely used in Hospital, Clinic and other field. The most proportion of ICAD (Intracranial Atherosclerotic Disease) Pathology is Hospital, and the consumption proportion in 2017 is about 63%.
North America is the largest Sales place, with a Sales market share nearly 26% in 2017. Following North America, Europe is the second largest Sales place with the Sales market share of 20%.
Market competition is intense. Stryker, Balt, TERUMO, MicroPort, Acandis, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global ICAD (Intracranial Atherosclerotic Disease) Pathology market is valued at 130 million US$ in 2017 and will reach 260 million US$ by the end of 2025, growing at a CAGR of 8.8% during 2018-2025.
The major manufacturers covered in this report
Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
Other regions (Central & South America, Middle East & Africa)
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
primarily split into
By Application, the market can be split into
The study objectives of this report are:
To analyze and study the global ICAD (Intracranial Atherosclerotic Disease) Pathology capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
Focuses on the key ICAD (Intracranial Atherosclerotic Disease) Pathology manufacturers, to study the capacity, production, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of ICAD (Intracranial Atherosclerotic Disease) Pathology are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.